Hereditum LC40


Probiotics isolated from human breast milk


Lactobacillus fermentum CECT5716, LC40 is a probiotic strain isolated from human breast milk of healthy mothers and under patent of Biosearch Life.

Lactobacillus fermentum CECT5716 LC40 can modulate human defences, reducing the risk of infections and alleviating inflammatory responses in several chronic inflammatory diseases.

Download Brochure

If you are interested to receive more information about this product, please give us your data in the following form and we will send you a PDF to your email.

    I have read and accept the Privacy Policy*

    I agree to receive commercial communications*


    Clinically validated, own safety and efficacy studies. LC40 possesses QPS (EFSA) and GRAS (FDA) status which guarantees the safety of the strain. Daily administration of LC40 is safe and well tolerated in adults and children.

    • LC40 is able to colonise the human gut.
    • LC40 produces compounds that help to maintain the integrity of human gut.
    • LC40 protects against intestinal infections.

    LC40 enhances immune response against pathogens.

    L. fermentum CECT5716, LC40 has been identified and characterised using biochemical, molecular and genetic techniques carried out in different Research Centres including The Institute Food Research (UK) and NIZO (Holland).

    Protection: L. fermentum CECT5716 is patented in the World Intellectual property
    Organization (WO/2004/003235).

    Stability studies performed in different applications (Food and Food supplements). Expertise: successful addition to a wide variety of finished products like infant formula and food supplements.


    Breast milk is the gold standard of infant nutrition since it not only covers the baby’s nutritional needs but also protects it from infections and diseases. The importance of breast milk in the development of intestinal flora, the modulation of the inmune system and the prevention of infections in newborns is a well documented fact.

    Frequency of mothers suffering breast pain is higher during the first month of breastfeeding. Antibiotic consumption during pregnancy
    or delivery is an important risk factor for mastitis development.

    Lactobacillus fermentum CECT5716 might be used as an efficient strategy to prevent development of lactational mastitis in women through reduction of the Staphylococcus load in breast milk.

    Less episodes of mastitis lead to a lesser use of antibiotics during breastfeeding and therefore a smaller risk of microbiota imbalance.

    L. fermentum CECT5716 (LC40) could be an efficient treatment for breast pain during lactation associated with high level of Staphylococcus in breastmilk.

    Click to see Bibliography

    Arroyo R, Martín V, Maldonado A et al. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin Infect Dis 2010 15;50(12):1551-8. Jose A. Maldonado-

    Lobón, Miguel A. Díaz-López et al. Lactobacillus fermentum CECT5716 reduces Staphylococcus load in the breast milk of lactating mothers suffering breast pain: A randomized controlled trial.

    Breastfeed Med. 2015 Nov;10:425-32. JA. Hurtado et al. Lactobacillus fermentum CECT5716, a human milk probiotic strain, reduces the incidence and symptoms of mastitis in lactating women. Poster presented at Probiota 2016. Amsterdam.


    Long-term safety: a 3-year study shows that the early administration of L. fermentum CECT5716 in an infant formula is safe and does not produce measurable differences in children compared with a control formula.

    Human Milk Probiotic Lactobacillus fermentum CECT5716 reduces the Incidence of Gastrointestinal and Upper Respiratory Tract Infections in Infants.
    Maldonado et al. 2012, Hepatology and Nutrition.

    The consumption of L. fermentum was related to a significant reduction of 71% in the incidence of gastrointestinal infections compared to the infants fed without the probiotic strain.
    Gil-Campos et al. 2012, Pharmacological Research.

    The singular origin of Hereditum® makes its range of strains an exceptional candidate for use in infant nutrition, functional foods, health supplements etc.

    Their excellent probiotic potential and technological versatility ensures their maximum functionality and performance (e.g. dairy products, fermented or not, sugar rich matrices, infant formulas, supplements, and many others).

    Contact Us

    FSSC 22000*
    ISO 22000*
    GMP –Good Manufacturing Practices- Food**
    Accreditation ISO 17025
    NDI (FDA): LC40 (Lactobacillus fermentum CECT5716)
    GRAS (FDA): LC40 (Lactobacillus fermentum CECT5716)
    QPS: All our strains are QPS in Europe.

    HEREDITUM® is patented
    in the World Intellectual
    property Organization

    *Design, production and distribution of oils, herbal extract and probiotics area.
    **xDesign, production and distribution of oils and probiotic area